section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus.

Resp: cough, dyspnea.

CV: ARRHYTHMIAS, HF, peripheral edema, chest pain, hypotension, palpitations, syncope, tachycardia.

GI: anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, liver enzymes, nausea, vomiting.

GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency.

Derm: dermatitis, erythema multiforme, flushing, sweating, photosensitivity, pruritus/urticaria, rash.

Endo: gynecomastia, hyperglycemia.

Hemat: anemia, leukopenia, thrombocytopenia.

Metab: weight gain.

MS: joint stiffness, muscle cramps.

Neuro: paresthesia, tremor , headache, abnormal dreams, anxiety, confusion, dizziness, drowsiness, nervousness, psychiatric disturbances, weakness.
Misc: STEVENS-JOHNSON SYNDROME, gingival hyperplasia.

Interactions

Drug-Drug:

Drug-Food:

Availability

(Generic available)

Route/Dosage

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antianginals, antihypertensives

Pharmacologic Classification: calcium channel blockers

Pharmacokinetics

Absorption: Well absorbed after oral administration, but extensively metabolized, resulting in bioavailability.

Distribution: Unknown.

Protein Binding: >99%.

Metabolism/Excretion: Mostly metabolized; minimal amounts excreted unchanged by kidneys.

Half-life: 11–16 hr.

Canadian Brand Names

Plendil

Time/Action Profile

(antihypertensive effect)

ROUTEONSETPEAKDURATION
PO1 hr2–4 hrup to 24 hr

Patient/Family Teaching

Pronunciation

fe-LOE-di-peen audio